ATS 2020 Advance Program

NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES L3 SEPSIS RESEARCH AT THE NIH 12:15 p.m. - 1:15 p.m. Target Audience Sepsis researchers, clinical and basic,and anyone interested in applying for NIH funding, fellows/trainees with an interest in critical care or sepsis. Objectives At the conclusion of this session, the participant will be able to: • learn and understand the types of sepsis research supported by different NIH institutes; • understand the different types of grant mechanisms that NIH uses to support sepsis research; • identify new and emerging areas of sepsis research that are needed to improve patient outcomes. This session will provide a brief overview of how sepsis research is funded by the NIH. Representatives from the primary NIH institutes that fund sepsis research (NIGMS, NHLBI, NIAID, NICHD) will describe their portfolios in terms of grant mechanisms and scientific topics. Emerging areas of sepsis research and shared resources available to sepsis researchers will be highlighted. Chairing: S. Dunsmore, PhD, Bethesda, MD L. Reineck, MD, Bethesda, MD 12:15 NHLBI Sepsis Research L. Reineck, MD, Bethesda, MD 12:30 NIAID Sepsis Research N. Ernst, PhD, Rockville, MD 12:45 NICHD Sepsis Research R.F. Tamburro, MD, MSc 1:00 NIGMS Sepsis Research S. Dunsmore, PhD, Rockville, MD NIAID, TB, LEPROSY AND OTHER MYCOBACTERIAL DISEASES L4 INHALATION THERAPY FOR NON-TUBERCULAR MYCOBACTERIAL PULMONARY INFECTIONS 12:15 p.m. - 1:15 p.m. Target Audience Scientists and clinicians studying therapeutic care for patients with non-tubercular mycobacterial infections or co-infections of the lung. Objectives At the conclusion of this session, the participant will be able to: • learn the characteristics of successful delivery of antibiotic drugs by inhalation; • understand the therapeutic options available for patients with cystic fibrosis and mac infections; • learn new antibiotic approaches in the pipeline. Novel approaches for delivery of antibiotics directly to the lungs through inhalation are being developed by research scientists supported by the National Institutes of Health. An overview of the current pipeline of new or re-purposed drugs for non-tuberculosis mycobacterial infections will be described. Three ongoing projects will be presented on development of novel formulations and approaches for treatment. Chairing: B.E. Laughon, PHD, Baltimore, MD J. Boyce, PhD, Bethesda, MD 12:15 Introduction to Session B.E. Laughon, PhD, Baltimore, MD 12:20 Drug Development Pipeline for NTMs C.L. Daley, MD, Denver, CO 12:25 Overview of Inhalation Approach to NTM Treatment A. Hickey, PhD, Research Triangle Park, NC 12:40 Pulmonary Clofazimine for M. abscessus B. Hansen, PhD, Longmont, CO ATS 2020 • Philadelphia, PA SUNDAY • MAY 17 49